Conquest Research

Rani Therapeutics has entered into an #agreement with ProGen for the co-development and commercialization of RT-114, an oral RaniPill capsule, for the treatment of #obesity. RT-114 contains ProGen’s PG-102, a GLP-1/GLP-2 dual agonist. Rani is designated to lead operationally in conducting preclinical and development activities through the #Phase1 program, which is expected to initiate in 2025. #weightloss #weightmanagement #collaboration

Eli Lilly and Company will acquire Morphic Therapeutic in a deal valued at $3.2B that includes an experimental oral medication for inflammatory bowel disease. Morphic develops oral integrin therapies including its most advanced drug, MORF-057, currently in three mid-stage studies as a potential treatment for two conditions: #ulcerativecolitis and #CrohnsDisease. Morphic is also developing unspecified treatments for other #autoimmunediseases, pulmonary hypertensive diseases, chronic diseases and #cancers. #immunology #inflammatory

We wish everyone a safe and fun #JulyFourth weekend. #ConquestResearch

#ConquestResearch will be closed this Thursday and Friday for the upcoming July 4th holiday.

Today, the FDA approves donanemab, a monoclonal antibody designed to slow the progression of early symptomatic #AlzheimersDisease. In a study of more than 1,730 patients, Eli Lilly and Company’s drug slowed patients’ decline by 35% compared with people who received a placebo. Last month, the FDA panel voted unanimously in favor of the drug’s benefits outweighing its risks. Lilly will market the drug under the name Kisunla. This follows another Alzheimer’s disease-modifying drug, Leqembi, introduced last year by Eisai and Biogen. #milestone  

#ConquestResearch had the privilege of providing an educational seminar for the CENTRAL FLORIDA ADVANCED NURSING PRACTICE COUNCIL. Dr. Patel led a discussion focusing on Clinical Research as a Care Option (CRAACO). #CRAACO is a method of connecting patients with #clinicaltrials as part of their ongoing health care programs. Introducing patients to clinical trials as part of their healthcare can improve patient outcomes, provide increased access to resources, and expedite new drug development. If providers encounter patients with memory concerns, referring patients for memory assessments can help facilitate early diagnosis and treatment of #AlzheimersDisease.

SNK01, a natural killer (NK) #celltherapy being developed by NKGen Biotech, Inc., has received clearance from its Safety Review Committee to advance into the #Phase2 part of a #clinicaltrial that is testing the treatment in people with moderate #AlzheimersDisease. The Phase 2 part will further assess SNK01’s safety and efficacy in about 30 patients randomly assigned to receive it every three weeks, or a placebo, for up to a year. The study is currently enrolling patients in Glendale, California. #alzheimers #endalz

UB-312, a therapeutic #vaccine candidate from Vaxxinity, safely led to antibodies being produced that could target toxic clumps of the alpha-synuclein protein in people with #ParkinsonsDisease, according to final published data from a #Phase1 #clinicaltrial. Twelve of 13 patients who completed dosing developed blood antibodies. Earlier this year, Vaxxinity entered into a research #collaboration with the University of Florida to advance the development of vaccines for #neurodegenerativediseases, including UB-312.

Eli Lilly and Company has revealed results from the SURMOUNT-OSA #Phase3 #clinicaltrials where #tirzepatide demonstrated to lower the severity of moderate-to-severe #obstructivesleepapnea (OSA) in obese adults irrespective of positive airway pressure (PAP) therapy status. Results were presented at the American Diabetes Association's 84th Scientific Sessions. Tirzepatide met all primary and key secondary endpoints. An approval decision for tirzepatide to treat #OSA and #obesity will be expected by the end of the year. #ADASciSessions 

The #collaboration between Roche and Ascidian Therapeutics will combine Ascidian's RNA Exon Editing platform with Roche’s next-generation CNS delivery capabilities to develop novel #RNA therapeutics targeting difficult-to-treat #neurologicaldiseases. Ascidian will receive $42M in initial payment, and up to a potential $1.8B in milestone payments and royalties. Per-target agreement enables Ascidian to pursue additional internal and collaborative programs within #neurology and other therapeutic areas.